A M Tsimberidou
Affiliation: The University of Texas
- Said R, Kakadiaris E, Piha Paul S, Fu S, Falchook G, Janku F, et al. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol. 2016;77:1097-102 pubmed publisher..8 and 5.5 months, respectively. The combination of lenalidomide with bevacizumab in patients with advanced solid tumors was safe. Prolonged stable disease was noted in selected tumor types, warranting further clinical evaluation. ..
- Said R, Ye Y, Hong D, Naing A, Falchook G, Fu S, et al. Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 2016;77:575-81 pubmed publisher..5 months (range <1.6-23), respectively. Lenalidomide in combination with FOLFOX was well tolerated. Four patients had prolonged stable disease. This combination merits further investigation for selected patient populations. ..
- Liu X, George G, Tsimberidou A, Naing A, Wheler J, Kopetz S, et al. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. BMC Cancer. 2015;15:713 pubmed publisher..156). Our data lends support to the concept of clonal evolution, though the clinical impact appears less robust than previously reported. Further work to determine which patients benefit from retreatment post progression is needed. ..
- Tsimberidou A, Rudek M, Hong D, Ng C, Blair J, Goldsweig H, et al. Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. Cancer Chemother Pharmacol. 2010;65:235-41 pubmed publisher..This phase I first-in-human trial evaluated salirasib, an S-prenyl derivative of thiosalicylic acid that competitively blocks RAS signaling...